BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 32956627)

  • 21. Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.
    Sentman ML; Murad JM; Cook WJ; Wu MR; Reder J; Baumeister SH; Dranoff G; Fanger MW; Sentman CL
    J Immunol; 2016 Dec; 197(12):4674-4685. PubMed ID: 27849169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models.
    Zheng L; Ren L; Kouhi A; Khawli LA; Hu P; Kaslow HR; Epstein AL
    Clin Cancer Res; 2020 Jul; 26(14):3694-3706. PubMed ID: 32273277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D RNA CAR.
    Li Z; Chi Z; Ang WX; Chen C; Tay JC; Ng YY; Xu X; Wang J; Zhu J; Wang S
    Immunotherapy; 2020 Jul; 12(10):733-748. PubMed ID: 32571133
    [No Abstract]   [Full Text] [Related]  

  • 26. Reducing Hinge Flexibility of CAR-T Cells Prolongs Survival
    Zhang A; Sun Y; Du J; Dong Y; Pang H; Ma L; Si S; Zhang Z; He M; Yue Y; Zhang X; Zhao W; Pi J; Chang M; Wang Q; Zhang Y
    Front Immunol; 2021; 12():724211. PubMed ID: 34675920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.
    Zhang Y; Liang K; Zhou X; Zhang X; Xu H; Dai H; Song X; Yang X; Liu B; Shi T; Wei J
    Cancer Sci; 2023 Jul; 114(7):2798-2809. PubMed ID: 37151176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T cells engineered with full-length NKG2D linked to signaling domains of 4-1BB and CD3ζ show enhanced antitumor activity.
    Teng X; Rong Z; Li S; Yang W; Lu Z
    Immunol Cell Biol; 2023 May; 101(5):458-464. PubMed ID: 36811384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors.
    Wang E; Wang LC; Tsai CY; Bhoj V; Gershenson Z; Moon E; Newick K; Sun J; Lo A; Baradet T; Feldman MD; Barrett D; Puré E; Albelda S; Milone MC
    Cancer Immunol Res; 2015 Jul; 3(7):815-26. PubMed ID: 25941351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer.
    Zhang Y; Li X; Zhang J; Mao L
    Biomed Pharmacother; 2020 Nov; 131():110562. PubMed ID: 32920508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.
    VanSeggelen H; Hammill JA; Dvorkin-Gheva A; Tantalo DG; Kwiecien JM; Denisova GF; Rabinovich B; Wan Y; Bramson JL
    Mol Ther; 2015 Oct; 23(10):1600-10. PubMed ID: 26122933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
    Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
    Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death.
    Wu L; Liu F; Yin L; Wang F; Shi H; Zhao Q; Yang F; Chen D; Dong X; Gu Y; Xing N
    Cancer Commun (Lond); 2022 Aug; 42(8):768-783. PubMed ID: 35706368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma.
    Meister H; Look T; Roth P; Pascolo S; Sahin U; Lee S; Hale BD; Snijder B; Regli L; Ravi VM; Heiland DH; Sentman CL; Weller M; Weiss T
    Clin Cancer Res; 2022 Nov; 28(21):4747-4756. PubMed ID: 36037304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
    Han Y; Xie W; Song DG; Powell DJ
    J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.
    Song DG; Ye Q; Santoro S; Fang C; Best A; Powell DJ
    Hum Gene Ther; 2013 Mar; 24(3):295-305. PubMed ID: 23297870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 40. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
    Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
    Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.